What Is GLP-1? Hormone, Receptor Agonists, and Research
Learn what native GLP-1 does, how GLP-1 receptor agonists differ from the hormone, and what clinical trials show about glucose, weight, and cardiovascular outcomes.
Glucagon-like peptide-1 (GLP-1) is a peptide hormone released after eating. It helps coordinate insulin secretion, glucagon signaling, gastrointestinal motility, and appetite. The term “GLP-1” is also used loosely for prescription drugs that activate the same receptor, but the native hormone and those medicines are not the same thing.
This guide separates the physiology from the drug class and distinguishes established human evidence from emerging research.
GLP-1 quick reference
| Question | Short answer |
|---|---|
| What is GLP-1? | An endogenous peptide hormone produced from proglucagon, primarily in intestinal L cells after nutrient intake |
| What does it do? | Supports glucose-dependent insulin secretion, restrains glucagon after meals, slows gastrointestinal activity, and contributes to satiety |
| How long does native GLP-1 last? | Only a few minutes because it is rapidly inactivated, largely by dipeptidyl peptidase-4 (DPP-4) |
| Is semaglutide GLP-1? | No. Semaglutide is a longer-acting GLP-1 receptor agonist engineered to activate the same receptor |
| Are all incretin drugs GLP-1-only agonists? | No. Tirzepatide activates GIP and GLP-1 receptors; retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist |
What does GLP-1 stand for?
GLP-1 stands for glucagon-like peptide-1. It is produced when the proglucagon precursor is processed in intestinal endocrine cells and selected neurons. Nutrients entering the gut stimulate its release.
The active hormone is short-lived. DPP-4 rapidly cleaves native GLP-1, giving it a circulating half-life of roughly two minutes. That short duration is one reason native GLP-1 itself is not used like a weekly medicine. Long-acting receptor agonists use structural changes, albumin binding, or other strategies to resist degradation and remain active longer. The underlying physiology and receptor pharmacology are reviewed in detail by Holst and de Graaf and colleagues.
How GLP-1 signaling works
GLP-1 binds the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic, gastrointestinal, neural, and other tissues. Its effects depend on tissue, nutrient state, glucose concentration, and whether the signal comes from a brief pulse of native hormone or sustained drug exposure.
Insulin secretion
GLP-1 amplifies insulin release when glucose is elevated. This glucose dependence matters: GLP-1 signaling does not simply force the same insulin output at every glucose level. The response helps limit the rise in blood glucose after a meal.
Glucagon regulation
GLP-1 can restrain glucagon secretion after nutrient intake. Because glucagon promotes hepatic glucose output, this effect works alongside insulin secretion to reduce post-meal glucose excursions. The interaction is context-dependent rather than a permanent shutdown of glucagon.
Gastric emptying and gastrointestinal signaling
Native GLP-1 participates in the “ileal brake,” a set of signals that slows upper-gastrointestinal activity when nutrients reach the distal gut. Human infusion studies support direct effects on gastric emptying, appetite, and food intake rather than requiring pancreatic amylin release to explain the entire response (Asmar et al., 2010).
Appetite and energy intake
GLP-1 receptor signaling reaches neural circuits involved in satiation and food reward. In clinical studies, longer-acting agonists can reduce energy intake and body weight. The magnitude varies by molecule, dose, trial population, treatment duration, adherence, and what happens after treatment stops.
Native GLP-1 versus GLP-1 receptor agonists
| Feature | Native GLP-1 | GLP-1 receptor agonist medicine |
|---|---|---|
| Source | Produced in the body | Manufactured peptide or, for some candidates, a non-peptide molecule |
| Exposure | Brief pulses after meals | Sustained exposure based on the product formulation |
| Duration | Minutes | Hours to days, depending on the medicine |
| Purpose | Physiologic nutrient signaling | A product-specific, regulator-reviewed indication such as type 2 diabetes or chronic weight management |
| Evidence | Physiology and experimental studies | Randomized trials, safety studies, outcome trials, and prescribing information for the individual product |
“GLP-1 medication” is therefore a convenient class label, not proof that every product has the same targets, indications, dosing, benefits, or risks.
What clinical trials show
Glucose control and cardiovascular outcomes
GLP-1 receptor agonists were first developed around glucose regulation in type 2 diabetes. In SUSTAIN-6, semaglutide was studied in people with type 2 diabetes at high cardiovascular risk. The composite rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was lower with semaglutide than placebo, while gastrointestinal discontinuations and retinopathy complications were more frequent in the semaglutide group (Marso et al., 2016). Those findings apply to the studied population and regimen; they are not a class-wide guarantee.
Weight-management trials
In STEP 1, adults with obesity or overweight plus a weight-related condition, without diabetes, received semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks. Semaglutide produced greater average weight reduction, but gastrointestinal events and treatment discontinuation were also more common (Wilding et al., 2021).
Tirzepatide is not a GLP-1-only agonist. It activates both GIP and GLP-1 receptors. SURMOUNT-1 found greater average weight reduction with tirzepatide than placebo over 72 weeks in adults with obesity or overweight plus a complication, excluding diabetes (Jastreboff et al., 2022). Cross-trial comparisons should be treated cautiously because populations, protocols, doses, and durations differ.
Cardiovascular outcomes without diabetes
SELECT enrolled adults with established cardiovascular disease and overweight or obesity but no diabetes. The primary cardiovascular outcome occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo; adverse events leading to permanent discontinuation were more frequent with semaglutide (Lincoff et al., 2023). This result is important, but it does not establish the same benefit for lower-risk populations or every drug that includes GLP-1 receptor activity.
How newer multi-receptor agonists differ
- Semaglutide is a GLP-1 receptor agonist.
- Tirzepatide activates GIP and GLP-1 receptors.
- Retatrutide activates GIP, GLP-1, and glucagon receptors. Published phase 2 results exist, while later-stage trials continue; it should not be described as an approved medicine (Jastreboff et al., 2023; ClinicalTrials.gov).
Adding receptor targets may change efficacy, tolerability, and physiology. It also makes “GLP-1” an increasingly incomplete shorthand for the broader incretin field. See the incretin agonist comparison for a molecule-by-molecule research overview.
Safety and interpretation
Safety information is product-specific. For semaglutide used in chronic weight management, current U.S. prescribing information lists gastrointestinal reactions among the most common adverse events and includes contraindications, warnings, drug-interaction considerations, and pregnancy guidance. It also carries a boxed warning based on thyroid C-cell tumors in rodents; whether that finding predicts the same risk in humans remains uncertain. Read the current FDA prescribing information rather than treating a class summary as personal guidance.
Important limits when reading GLP-1 research:
- A randomized trial estimates an average treatment effect in a defined population; it does not predict one person’s outcome.
- Benefits and adverse events reported for one molecule or indication should not be copied to another.
- Weight-change percentages are not directly comparable across trials with different designs.
- Investigational compounds do not have an established clinical benefit-risk profile or approved prescribing information.
- Product authenticity, formulation, and medical supervision are separate issues from whether a receptor mechanism is scientifically plausible.
PepGuide provides research context, not diagnosis, prescribing, or individualized treatment advice.
Frequently asked questions
Is GLP-1 a peptide or a drug?
Native GLP-1 is a peptide hormone. “GLP-1 drug” usually refers to a medicine that activates the GLP-1 receptor. Some are peptide analogs; newer research also includes non-peptide receptor agonists.
Is GLP-1 the same as semaglutide?
No. GLP-1 is the endogenous hormone. Semaglutide is an engineered, longer-acting receptor agonist with product-specific clinical evidence and regulatory labeling.
Does GLP-1 always cause insulin release?
Its insulinotropic effect is glucose-dependent, meaning the response becomes more important when glucose is elevated. Hypoglycemia risk still depends on the medicine, dose, concurrent therapies, and patient context.
Why do GLP-1 receptor agonists affect body weight?
Their effects can include reduced appetite and energy intake, altered gastrointestinal signaling, and improved glucose regulation. The contribution of each pathway varies, and weight response differs among people and products.
Does slower gastric emptying explain every effect?
No. Gastric emptying is one mechanism, but pancreatic, neural, and other signaling pathways also contribute. The effect on gastric emptying can vary with the molecule and duration of exposure.
References
- Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007. PMID: 17928588
- de Graaf C, et al. Glucagon-like peptide-1 and its class B G-protein-coupled receptors. Pharmacological Reviews. 2016. PMID: 27630114
- Asmar M, et al. Actions of GLP-1 on gastric emptying, appetite, and food intake. Journal of Clinical Endocrinology & Metabolism. 2010. PMID: 20194711
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016. PMID: 27633186
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. PMID: 33567185
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. PMID: 35658024
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023. PMID: 37952131
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. 2023. PMID: 37366315
- FDA. Wegovy prescribing information. Revised February 2026.
See also
Tesamorelin vs Sermorelin: FDA Status and Evidence
Compare tesamorelin and sermorelin by mechanism, FDA status, studied population, clinical outcomes, safety evidence, and limits of head-to-head claims.
What Is IGF-1? Biology, Testing, and Clinical Evidence
Understand IGF-1 biology, growth hormone regulation, binding proteins, lab interpretation, FDA-approved mecasermin use, and the limits of IGF-1 LR3 claims.